Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15033673rdf:typepubmed:Citationlld:pubmed
pubmed-article:15033673lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0015730lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C1519810lld:lifeskim
pubmed-article:15033673lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:15033673pubmed:issue4lld:pubmed
pubmed-article:15033673pubmed:dateCreated2004-3-22lld:pubmed
pubmed-article:15033673pubmed:abstractTextTo determine the safety profile and activity of the combination of docetaxel, cisplatin and 5-fluorouracil (5-FU) in chemotherapy-naive patients with squamous cell carcinoma of the head and neck (SCCHN).lld:pubmed
pubmed-article:15033673pubmed:languageenglld:pubmed
pubmed-article:15033673pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:citationSubsetIMlld:pubmed
pubmed-article:15033673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15033673pubmed:statusMEDLINElld:pubmed
pubmed-article:15033673pubmed:monthAprlld:pubmed
pubmed-article:15033673pubmed:issn0923-7534lld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:NguyenHHlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:De MulderPPlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:VermorkenJ...lld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:AwadaAAlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:Van LaerCClld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:SchrijversDDlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:CastelijnsJ...lld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:KergerJJlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:Van den...lld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:JoosensEElld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:KaandersJJlld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:Van HerpenCClld:pubmed
pubmed-article:15033673pubmed:authorpubmed-author:Le BouderCClld:pubmed
pubmed-article:15033673pubmed:issnTypePrintlld:pubmed
pubmed-article:15033673pubmed:volume15lld:pubmed
pubmed-article:15033673pubmed:ownerNLMlld:pubmed
pubmed-article:15033673pubmed:authorsCompleteYlld:pubmed
pubmed-article:15033673pubmed:pagination638-45lld:pubmed
pubmed-article:15033673pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:meshHeadingpubmed-meshheading:15033673...lld:pubmed
pubmed-article:15033673pubmed:year2004lld:pubmed
pubmed-article:15033673pubmed:articleTitleDocetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.lld:pubmed
pubmed-article:15033673pubmed:affiliationUniversity Hospital Antwerp, Edegem, Belgium.lld:pubmed
pubmed-article:15033673pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15033673pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15033673pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:15033673pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:15033673pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15033673lld:pubmed